Table 2.

Cardiovascular Biomarkers and Outcomes According to Treatment (N = 252)

	Non-ICI (n = 117)	ICI (n = 135)	p Value
Post-treatment LVEF∗	55.6 ± 11.6	53.8 ± 14.1	0.46
Elevated serum troponin I†	7 (6.0)	22 (16.3)	0.01
Initial, ng/ml	2.6 ± 4.9	3.3 ± 10.8	0.87
Peak, ng/ml	2.8 ± 4.9	9.2 ± 18.1	0.37
Median time to elevation, days	38 (12–157)	36 (6–152)	0.88
Number of measurements	3 (0–7)	4 (1–8)	0.01
Elevated serum BNP‡	34 (28.2)	47 (34.8)	0.261
Level, pg/ml	515 ± 908	453 ± 456	0.687
Median time to elevation, days	54 (9–161)	57 (22–245)	0.42
Number of measurements	2 (0–3)	2 (1–4)	0.02
All-cause death	33 (28.2)	51 (37.8)	0.14
Major adverse cardiovascular events§	12 (10.3)	18 (13.3)	0.45
Cardiovascular death	7 (6.0)	13 (9.6)	0.95
Nonfatal myocardial infarction	1 (0.9)	1 (0.7)	0.92
Nonfatal stroke	1 (0.9)	0 (0.0)	0.28
Hospitalization for heart failure	3 (2.6)	4 (3.0)	0.85
Cardiovascular adverse events per CTCAE (version 5.0)	42 (35.9)	51 (37.8)	0.76
Arrhythmia	31 (26.5)	25 (18.5)	0.13
Cardiac-related chest pain	12 (10.3)	25 (18.5)	0.07
Valvular heart disease	4 (3.4)	2 (1.5)	0.31
Cardiomyopathy	13 (11.1)	20 (14.8)	0.39
Myopericardial disease	11 (9.4)	9 (6.7)	0.42

Values are mean ± SD, n (%), or median (interquartile range).

BNP = B-type natriuretic peptide; CTCAE = Common Terminology Criteria of Adverse Events, version 5.0; ICI = immune checkpoint inhibitor; LVEF = left ventricular ejection fraction; MACE = major adverse cardiac events.

^∗Post-treatment LVEF was determined by the most recent transthoracic echocardiogram in 47 of 117 of non-ICI– and 47 of 135 of ICI-treated patients.

^†Serum TnI was measured in 203 of 252 patients.

^‡Serum BNP was measured in 193 of 252 patients.

^§MACE is defined as the first event within the composite endpoint to occur. Some patients developed multiple events during their treatment course though only the first event occurring during therapy is listed in this table.